Stephens & Co. Initiates Coverage On Cytek Biosciences With Overweight Rating, Announces Price Target of $9
Stephens & Co. Initiates Coverage On Cytek Biosciences With Overweight Rating, Announces Price Target of $9
Stephens & Co.以增持評級啓動對Cytek Biosciences的報道,宣佈目標股價爲9美元
Stephens & Co. analyst Mason Carrico initiates coverage on Cytek Biosciences (NASDAQ:CTKB) with a Overweight rating and announces Price Target of $9.
斯蒂芬斯公司分析師梅森·卡里科以增持評級開始對Cytek Biosciences(納斯達克股票代碼:CTKB)進行報道,並宣佈目標股價爲9美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。